| P2093 | author name string | Cannon CP | |
| | Tracy R | |
| P2860 | cites work | Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation | Q24337851 |
| | Structure of the hirugen and hirulog 1 complexes of alpha-thrombin | Q27655399 |
| | The structure of a complex of recombinant hirudin and human alpha-thrombin | Q27684792 |
| | Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors | Q28294390 |
| | The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action | Q28298065 |
| | Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces | Q28630174 |
| | Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 |
| | Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 |
| | Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis | Q33351903 |
| | Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes | Q33362637 |
| | Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study | Q33493712 |
| | Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study | Q34247562 |
| | Regulation of activated protein C by a new protein. A possible function for bovine protein S. | Q34272904 |
| | Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty | Q34336722 |
| | Aspirin as an antiplatelet drug | Q34338650 |
| | Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis | Q34369110 |
| | Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis | Q34551515 |
| | A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery | Q34689934 |
| | Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation | Q35047906 |
| | The Use of Aspirin in Ischemic Heart Disease | Q35176153 |
| | Protection of factor Xa from neutralization by the heparin-antithrombin complex | Q35207027 |
| | Molecular and cellular biology of blood coagulation | Q35896519 |
| | The role of tissue factor pathway inhibitor in a revised coagulation cascade | Q36370143 |
| | The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 |
| | Oral anticoagulant drugs | Q37003395 |
| | Correlation between structure and function of heparin | Q37320355 |
| | Structure-function relationships of heparin species | Q37589663 |
| | The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence Chemical and13C nuclear-magnetic-resonance studies | Q38356062 |
| | Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis | Q38735182 |
| | The regulation of hemostasis: the protein C system | Q39501234 |
| | Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty | Q40541708 |
| | Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. | Q40918338 |
| | A Brief Account of a Disease in Cattle Simulating Hemorrhagic Septicaemia due to Feeding Sweet Clover. | Q42968059 |
| | The effect of warfarin on mortality and reinfarction after myocardial infarction | Q44339433 |
| | Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody | Q44372589 |
| | Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy | Q44519440 |
| | Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI) | Q44806369 |
| | Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin | Q47431917 |
| | Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial | Q49173352 |
| | Pharmacokinetics and anticoagulant effect of hirudin in man. | Q52431805 |
| | Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. | Q52449650 |
| | A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. | Q53985201 |
| | Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. | Q54038510 |
| | Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months | Q56945638 |
| | Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor | Q60924822 |
| | Structure-function relationships of hirulog peptide interactions with thrombin | Q67791322 |
| | Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion | Q67984272 |
| | Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis | Q68053164 |
| | Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group | Q68158313 |
| | Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin | Q68577413 |
| | Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins | Q69174452 |
| | Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group | Q69364610 |
| | RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 | Q69755626 |
| | Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin | Q69875861 |
| | Mechanism of action and monitoring of anticoagulants | Q70037524 |
| | Heparin | Q70147507 |
| | A prospective study of aspirin use and primary prevention of cardiovascular disease in women | Q70215146 |
| | Aspirin, heparin, or both to treat acute unstable angina | Q70216460 |
| | Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex | Q70332055 |
| | Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects | Q70489173 |
| | Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease | Q70620179 |
| | Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris | Q70625383 |
| | Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group | Q71610586 |
| | Cellular cooperation in endothelial cell thromboplastin synthesis | Q71727038 |
| | Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial | Q71974437 |
| | Structural studies on a biologically active hexasaccharide obtained from heparin | Q72017116 |
| | Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction | Q72112981 |
| | Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators | Q72112987 |
| | Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association | Q72285055 |
| | A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial | Q72332452 |
| | Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial | Q72344112 |
| | Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio | Q72623669 |
| | Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial | Q72711397 |
| | Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators | Q72711401 |
| | Identification of the fibrinogen receptor on human platelets by photoaffinity labeling | Q72932817 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 95-106 | |
| P577 | publication date | 1995-01-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy | |
| P478 | volume | 2 | |